000119669 001__ 119669
000119669 005__ 20240228134948.0
000119669 0247_ $$2doi$$a10.3109/13506129.2013.854766
000119669 0247_ $$2pmid$$apmid:24455967
000119669 0247_ $$2ISSN$$a1350-6129
000119669 0247_ $$2ISSN$$a1744-2818
000119669 0247_ $$2altmetric$$aaltmetric:2072197
000119669 037__ $$aDKFZ-2017-00300
000119669 041__ $$aeng
000119669 082__ $$a610
000119669 1001_ $$0P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aBochtler, Tilmann$$b0$$udkfz
000119669 245__ $$aGain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone.
000119669 260__ $$aAbingdon$$bTaylor & Francis Group$$c2014
000119669 3367_ $$2DRIVER$$aarticle
000119669 3367_ $$2DataCite$$aOutput Types/Journal article
000119669 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1488542073_12067
000119669 3367_ $$2BibTeX$$aARTICLE
000119669 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000119669 3367_ $$00$$2EndNote$$aJournal Article
000119669 520__ $$aChromosomal aberrations of plasma cells are well established pathogenetic and prognostic factors in multiple myeloma, but their prognostic implication in systemic light chain (AL) amyloidosis is unclear. Therefore, the aim of this study was to identify prognostic cytogenetic risk factors by interphase FISH in a series of 103 consecutive AL amyloidosis patients treated uniformly with melphalan/dexamethasone as first-line therapy. Detection of gain of 1q21 was predictive for a poor overall survival (OS) (median 12.5 versus 38.2 months, p = 0.002). Hematologic event free survival (hem EFS) for gain of 1q21 was 5.0 versus 8.5 months in median (p = 0.08) and haematologic remission rates (≥VGPR) after three cycles were 5% versus 25% (p = 0.06). Most important, in multivariate concordance analyses the adverse prognosis carried by gain of 1q21 was retained as an independent prognostic factor (OS: p = 0.003, average hazard ratio (AHR) = 3.64, hemEFS: p = 0.008, AHR = 2.35), along with the well established Mayo cardiac staging. Patients with t(11;14) had a longer median OS with 38.2 months versus 17.5 months, though no statistical significance was reached. Deletion 13q14 and hyperdiploidy turned out to be prognostically neutral. In conclusion, we have identified gain of 1q21 as an independent adverse prognostic factor in AL amyloidosis patients treated with standard chemotherapy.
000119669 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000119669 588__ $$aDataset connected to CrossRef, PubMed,
000119669 650_7 $$2NLM Chemicals$$aImmunoglobulin Light Chains
000119669 650_7 $$07S5I7G3JQL$$2NLM Chemicals$$aDexamethasone
000119669 650_7 $$0Q41OR9510P$$2NLM Chemicals$$aMelphalan
000119669 7001_ $$aHegenbart, Ute$$b1
000119669 7001_ $$0P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aKunz, Christina$$b2$$udkfz
000119669 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, Axel$$b3$$udkfz
000119669 7001_ $$aSeckinger, Anja$$b4
000119669 7001_ $$0P:(DE-HGF)0$$aDietrich, Sascha$$b5
000119669 7001_ $$aGranzow, Martin$$b6
000119669 7001_ $$aNeben, Kai$$b7
000119669 7001_ $$0P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aGoldschmidt, Hartmut$$b8$$udkfz
000119669 7001_ $$aHo, Anthony D$$b9
000119669 7001_ $$aHose, Dirk$$b10
000119669 7001_ $$aJauch, Anna$$b11
000119669 7001_ $$aSchönland, Stefan O$$b12
000119669 773__ $$0PERI:(DE-600)2141924-3$$a10.3109/13506129.2013.854766$$gVol. 21, no. 1, p. 9 - 17$$n1$$p9 - 17$$tAmyloid$$v21$$x1744-2818$$y2014
000119669 909CO $$ooai:inrepo02.dkfz.de:119669$$pVDB
000119669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000119669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a9f6104e5c2c26345dcb242e6bdcb2b2$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000119669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000119669 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a1aa959d47e3e026abe157a8adf24b96$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000119669 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000119669 9141_ $$y2014
000119669 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000119669 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bAMYLOID : 2015
000119669 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000119669 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000119669 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000119669 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000119669 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000119669 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000119669 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000119669 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000119669 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000119669 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000119669 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000119669 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000119669 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x0
000119669 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000119669 980__ $$ajournal
000119669 980__ $$aVDB
000119669 980__ $$aI:(DE-He78)G330-20160331
000119669 980__ $$aI:(DE-He78)C060-20160331
000119669 980__ $$aUNRESTRICTED